Libmeldy: ‘Significant Discount’ For World’s Most Expensive Drug Secures English Funding
US Filing Planned In Late 2022 Or Early 2023
Executive Summary
Orchard Therapeutics has agreed to lower the price of its £2.8m gene therapy for children with metachromatic leukodystrophy following negotiations with the National Health Service. Meanwhile, reimbursement efforts in the rest of Europe are also gaining speed and a US filing is planned.
You may also be interested in...
New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe
Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.
Gene Therapy Cost Effectiveness: US ICER Supports Million-Dollar Prices
Institute for Clinical and Economic Review continues to assign high values to novel gene therapies, suggesting that Orchard’s pending ‘arsa-cel’ for MLD could be cost effective at a price as high as $4 million per treatment.
Kyowa Kirin Tries On New Genes With Orchard Buy
The Japan-based drug maker is hoping to expand into cell and gene therapy as well as enlarge its presence in the North American market, while Orchard awaits an FDA verdict on Libmeldy.